China Biologic Products (NASDAQ:CBPO) Cut to Hold at BidaskClub

BidaskClub lowered shares of China Biologic Products (NASDAQ:CBPO) from a buy rating to a hold rating in a research report report published on Tuesday morning, BidAskClub reports.

Several other equities research analysts also recently weighed in on CBPO. Zacks Investment Research downgraded China Biologic Products from a hold rating to a sell rating in a report on Thursday, August 15th. ValuEngine downgraded China Biologic Products from a buy rating to a hold rating in a report on Wednesday, September 4th. Two research analysts have rated the stock with a sell rating and four have issued a hold rating to the company’s stock. China Biologic Products currently has an average rating of Hold and an average price target of $78.00.

Shares of CBPO traded up $0.09 during mid-day trading on Tuesday, reaching $100.05. 17,088 shares of the company’s stock were exchanged, compared to its average volume of 120,326. The stock has a market capitalization of $3.94 billion, a PE ratio of 24.89, a price-to-earnings-growth ratio of 6.08 and a beta of 1.18. The business’s fifty day simple moving average is $98.19 and its 200-day simple moving average is $93.52. China Biologic Products has a 52-week low of $60.08 and a 52-week high of $103.50.



China Biologic Products (NASDAQ:CBPO) last announced its earnings results on Monday, August 5th. The biopharmaceutical company reported $1.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.03 by $0.21. The business had revenue of $135.70 million for the quarter. China Biologic Products had a net margin of 29.46% and a return on equity of 8.56%. The business’s revenue was up 12.7% on a year-over-year basis. During the same quarter last year, the business posted $1.17 earnings per share. As a group, equities analysts forecast that China Biologic Products will post 3.29 EPS for the current year.

A number of institutional investors have recently added to or reduced their stakes in the business. York Capital Management Global Advisors LLC lifted its holdings in China Biologic Products by 13.9% in the second quarter. York Capital Management Global Advisors LLC now owns 1,128,717 shares of the biopharmaceutical company’s stock valued at $107,567,000 after acquiring an additional 137,484 shares during the period. Vanguard Group Inc. increased its position in China Biologic Products by 3.2% during the 2nd quarter. Vanguard Group Inc. now owns 950,421 shares of the biopharmaceutical company’s stock worth $90,575,000 after purchasing an additional 29,178 shares in the last quarter. FIL Ltd increased its position in China Biologic Products by 1.8% during the 1st quarter. FIL Ltd now owns 519,071 shares of the biopharmaceutical company’s stock worth $47,365,000 after purchasing an additional 8,929 shares in the last quarter. Greenwoods Asset Management Ltd grew its holdings in China Biologic Products by 281.8% in the 1st quarter. Greenwoods Asset Management Ltd now owns 479,580 shares of the biopharmaceutical company’s stock valued at $43,762,000 after buying an additional 353,980 shares during the period. Finally, Maso Capital Partners Ltd grew its holdings in China Biologic Products by 3.3% in the 1st quarter. Maso Capital Partners Ltd now owns 164,500 shares of the biopharmaceutical company’s stock valued at $15,011,000 after buying an additional 5,300 shares during the period. 36.90% of the stock is owned by institutional investors.

About China Biologic Products

China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.

See Also: What is a short straddle?

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.